ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
source: unsplash.com

ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency

  The ENDO 2022 Annual Congress took place from June 11-14, 2022. During the Congress, stakeholders met to discuss care, treatments, and research within endocrinology. In a news release from…

Continue Reading ICYMI: Evaluating Sogroya for Pediatric Growth Hormone Deficiency
ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy
source: pixabay.com

ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy

  The patient, age 82, had recovered from a stroke several months ago. According to a recent article reported on dnyuz.com and originally published in the New York Times, the…

Continue Reading ICYMI: His Doctors Finally Discovered the Cause of His Immune-Mediated Necrotizing Myopathy
IK-930 for NF2-deficient Malignant Pleural Mesothelioma Earns Fast Track Designation
Source: https://unsplash.com/photos/ZHys6xN7sUE

IK-930 for NF2-deficient Malignant Pleural Mesothelioma Earns Fast Track Designation

  For some patients with NF2-deficient malignant pleural mesothelioma (MPM), their cancer is unresectable, meaning that it cannot be surgically removed. Finding a way to better treat and assist these…

Continue Reading IK-930 for NF2-deficient Malignant Pleural Mesothelioma Earns Fast Track Designation